Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial

[1]  H. Döhner,et al.  Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. , 2020, The New England journal of medicine.

[2]  M. Levis,et al.  Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia , 2020, Bone Marrow Transplantation.

[3]  C. Bloomfield,et al.  Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. , 2020, Blood advances.

[4]  K. Strauch,et al.  Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN). , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. Bloomfield,et al.  Impact of NPM1/FLT3-ITD genotypes defined by the2017 European LeukemiaNet in patients with acute myeloid leukemia. , 2019, Blood.

[6]  M. Levis,et al.  FLT3 inhibitors added to induction therapy induce deeper remissions. , 2019, Blood.

[7]  C. Gisselbrecht,et al.  European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis , 2019, ESMO Open.

[8]  R. Larson,et al.  Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. , 2019, The New England journal of medicine.

[9]  H. Dombret,et al.  Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. , 2019, The Lancet. Oncology.

[10]  R. Greil,et al.  Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. , 2019, Blood.

[11]  C. Bloomfield,et al.  FLT3mutation Assay Laboratory Cross Validation: Results from the CALGB 10603/Ratify Trial in Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) , 2018, Blood.

[12]  E. Estey,et al.  Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. , 2018, The Lancet. Oncology.

[13]  R. Larson,et al.  Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. , 2018, Blood advances.

[14]  M. Caligiuri,et al.  Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells , 2018, Nature Medicine.

[15]  K. Götze,et al.  Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation. , 2017, European journal of cancer.

[16]  L. Bullinger,et al.  Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO) , 2017, Annals of Hematology.

[17]  C. Bloomfield,et al.  Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation , 2017, The New England journal of medicine.

[18]  R. Larson,et al.  Selective Inhibition of FLT3 by Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia: a Multicenter, First-in-human, Open-label, Phase 1/2 Study , 2017, The Lancet. Oncology.

[19]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[20]  L. Bullinger,et al.  Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. , 2014, Blood.

[21]  C. Schiffer,et al.  Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia , 2012, Leukemia.

[22]  E. Estey,et al.  Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Levis,et al.  Bench to bedside targeting of FLT3 in acute leukemia. , 2010, Current drug targets.

[24]  M. Caligiuri,et al.  FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. , 2008, Blood.

[25]  A. Mead,et al.  FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. , 2007, Blood.

[26]  E. Estey,et al.  Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 , 2004 .

[27]  B. Smith,et al.  In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. , 2004, Blood.

[28]  G. Ehninger,et al.  Analysis of Flt3-activating Mutations in 979 Patients with Acute Myelogenous Leukemia: Association with Fab Subtypes and Identification of Subgroups with Poor Prognosis , 2022 .

[29]  Doriano Fabbro,et al.  Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. , 2002, Cancer cell.

[30]  M. Caligiuri,et al.  Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. , 2001, Cancer research.

[31]  H. Kaneko,et al.  Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. , 1996, Leukemia.